Stay updated with breaking news from Tropism Redirection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) and Voyager Therapeutics Inc. (VYGR) said that they have collaborated to advance multiple gene therapies for the treatment of neurological
Voyager Therapeutics has promising technology. But the stock is very risky.
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties ...
Novartis gains target-specific access to next-generation AAV capsids that could be used for three diseases of the central nervous system, with options for two additional targets
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access... | March 8, 2022